Clinical breast cancer最新文献

{"title":"Physician and Software Assessed Cosmetic Outcomes Following Whole Breast or Partial Breast Radiation Therapy for Breast Cancer.","authors":"Anna Okabe, Wai Lone J Ho, May Lin Tao, Jason C Ye","doi":"10.1016/j.clbc.2025.07.006","DOIUrl":"10.1016/j.clbc.2025.07.006","url":null,"abstract":"<p><strong>Aim: </strong>This study aims to compare the cosmetic outcomes in early-stage breast cancer patients treated with whole breast irradiation (WBI) or partial-breast irradiation (PBI), using both subjective and objective tools, to assess clinical factors contributing to cosmesis scores, and to compare radiation toxicity outcomes.</p><p><strong>Methods: </strong>Breast cosmesis was scored by using the physician-rated Harvard cosmesis scale at the time of consultation and at each follow-up visit and objectively using the BCCT.core software on standardized photographs.</p><p><strong>Results: </strong>Ninety-nine patients received WBI, and thirty-six received PBI. 91% of patients treated with WBI and 86.1% with PBI scored excellent/good by physician ratings at follow-up vs. 68.4% and 72.2 % by BCCT.core software. Agreement between both tools was low (κ = 0.057 for WBI patients and κ = 0.012 for PBI patients). There was less than a 15% decline in physician-rated cosmetic scores for either WBI or PBI patients, but a 27.3% decline for WBI patients by BCCT.core software scoring. There was no association of prone vs. supine position, tumor bed boost, fractionation scheme, or addition of regional nodal irradiation with long-term cosmesis scores determined by either assessment tool, except for oncoplastic surgery which was associated with a higher score.</p><p><strong>Conclusions: </strong>Breast cosmesis scores after either WBI or PBI are favorable; however, the agreement between physician rating and the BCCT.core software is poor. The BCCT.core software was more likely to indicate a decline in cosmetic results over time. Surgical outcomes may be the most impactful clinical factor in predicting long-term breast cosmesis.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12318241/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Area Deprivation Index (ADI) as a Predictor of Surgical Complications in Patients Undergoing Mastectomy.","authors":"Felix J Klimitz, Laetitia S Chiarella, Lioba Huelsboemer, Stav Brown, Sam Boroumand, Alejandro Kochen, Alexander J Kammien, SeungJu Jackie Oh, Martin Kauke-Navarro, Fortunay Diatta, Bohdan Pomahac","doi":"10.1016/j.clbc.2025.07.004","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.07.004","url":null,"abstract":"<p><strong>Introduction: </strong>Socioeconomic disparities significantly influence health outcomes, particularly in surgical care. The Area Deprivation Index (ADI), a comprehensive measure of neighborhood-level socioeconomic status, is increasingly recognized as a predictor of clinical outcomes. This study examines the association between ADI and postoperative complications in patients undergoing mastectomy, hypothesizing that higher ADI scores correlate with worse outcomes.</p><p><strong>Methods: </strong>A retrospective cohort analysis was conducted using the ACS-NSQIP database to evaluate 1141 female patients who underwent mastectomy between 2017 and 2022. Patients were categorized into tertiles based on their ADI scores. Preoperative characteristics, surgical details, and 30-day postoperative outcomes were analyzed. Statistical significance was assessed using chi-square tests for categorical variables and ANOVA for continuous variables.</p><p><strong>Results: </strong>Patients in the highest ADI tertile had significantly higher rates of medical complications (17.3%) compared to those in the lowest tertile (9.2%, P = .01). Pneumonia was notably more frequent in the most deprived group (4.7% vs. 0.8%, P = .01). Other complications, such as unplanned readmissions and surgical complications, showed no significant differences between tertiles. Black patients were disproportionately represented in the highest ADI tertile, highlighting intersectional disparities. Household income and insurance type varied significantly across ADI tertiles, reflecting broader socioeconomic inequities.</p><p><strong>Conclusion: </strong>Higher ADI scores are associated with increased medical complications, particularly pneumonia, in mastectomy patients. These findings emphasize the importance of integrating socioeconomic factors into surgical risk assessments and developing targeted interventions to address disparities in care and outcomes.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hidden Costs of Endocrine Therapy for Black Breast Cancer Survivors: A Qualitative Examination of Patient and Provider Experiences.","authors":"Kimberley T Lee, Carley Geiss, Hayden J Fulton, Dannelle Charles, Brian D Gonzalez, Heather S L Jim, N Lynn Henry, Dawn L Hershman, Shelley S Tworoger, Angela Bradbury, Oluwadamilola M Fayanju, Susan T Vadaparampil, Clement K Gwede","doi":"10.1016/j.clbc.2025.06.010","DOIUrl":"10.1016/j.clbc.2025.06.010","url":null,"abstract":"<p><strong>Background: </strong>Non-adherence to endocrine therapy (ET) remains an unsolved clinical issue that decreases rates of survival. Non-white race and socioeconomic status have been associated with ET non-adherence, but the reasons for these disparities are unclear. Addressing this issue effectively requires the characterization of the contributing factors to these inequities. This qualitative study aims to explore the influence of race and socioeconomic status on ET adherence through the perspectives of Black breast cancer survivors (BCS) and oncology providers.</p><p><strong>Methods: </strong>We conducted individual semi-structured interviews with 24 Black BCS and 9 providers at a single cancer center.</p><p><strong>Results: </strong>BCS had a median age of 55 years (IQR = 17 years). About 1/4 had ≤high school diploma (26.1%) and 37.7% completed ≥college education. About 1/3 of BCS had annual household incomes of ≤$40,000 (30.4%), $40,000 to $100,000 (34.8%), or ≥$100,000 (34.8%). Forty-three percent of BCS had private insurance; 39.1% were insured through Medicaid, Medicare, or the federal healthcare exchange; 13% were uninsured. Five qualitative themes emerged from both patients and providers: (1) Limited access to initial and continued care; (2) patient discomfort, distrust, and fear of discrimination; (3) cost of ET can be a barrier to adherence; (4) costs of managing symptoms can be a barrier to adherence; and (5) time toxicity - time and effort needed to coordinate symptom management.</p><p><strong>Conclusions: </strong>In addition to cost of ET medications, we identified additional financial and time toxicity related to side-effect management. Black BCS face a myriad of costs which can potentially impact ET adherence.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12415873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144717603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Potential Role of Ubiquitin-Conjugating Enzyme E2C (UBE2C) in Breast Cancer Progression by Regulating the JNK Signaling Pathway.","authors":"Siqi Liu, Xin Sun, Na Liu, Fangcai Lin","doi":"10.1016/j.clbc.2025.07.001","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.07.001","url":null,"abstract":"<p><strong>Background: </strong>We explored the relation and critical roles of ubiquitin-conjugating enzyme E2C (UBE2C) in breast cancer (BC).</p><p><strong>Methods: </strong>The UBE2C expression levels and relation with clinical features and prognosis in BC patients were examined using online data. UBE2C expression in BC cell lines was assessed using quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and western blot. To assess cell proliferation, migration, invasion, and apoptosis, tests were conducted using CCK-8, colony formation assay, wound healing assay, transwell assay, and flow cytometry. Subcutaneous tumor model was used to evaluate the effects of UBE2C on tumor growth in mice. The effects of UBE2C on tumor formation in mice were assessed by subcutaneous tumor model, and UBE2C, E-cadherin, Ki-67, and p53 were detected by an immunohistochemistry assay. Finally, the connection of UBE2C with Epithelial-mesenchymal transition markers and proteins of proliferation, apoptosis, JNK pathway were tested by western blot.</p><p><strong>Results: </strong>UBE2C was upregulated in BC tissues in TCGA and Gene expression omnibus (GEO) datasets, and high levels UBE2C was correlated with the advanced stage cases, some molecular types and poor prognosis in BC patients. In vitro, UBE2C was also overexpressed in BC cell lines, and suppressed apoptosis and encouraged cell growth, migration, invasion, and metastasis. Moreover, UBE2C knockdown suppressed the growth of transplanted tumor in mice.</p><p><strong>Conclusions: </strong>These results suggested that UBE2C facilitated the process of proliferation, metastasis through the modulation of the JNK signaling pathway, highlighting a previously underexplored mechanistic axis and predicting the potentiality of UBE2C as a therapeutic target for BC patients.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144717604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Level 1 Oncoplastic Technique for Breast Conserving Surgery: The Rhomboid Rotation Glandular Flap","authors":"Ashley DiPasquale,&nbsp;Anna Paula Maiato,&nbsp;Jenny-Claude Millochau,&nbsp;Isabelle Sarfati,&nbsp;Claude Nos,&nbsp;Krishna B. Clough","doi":"10.1016/j.clbc.2025.06.014","DOIUrl":"10.1016/j.clbc.2025.06.014","url":null,"abstract":"<div><div>OPS techniques have many advantages over standard lumpectomies. They allow for immediate breast reshaping, helping to eliminate postoperative defects, and they offer wider resection possibilities. Level I OPS techniques are those employed when less than 20% of the breast volume is excised, and no mammoplasty is needed for reshaping. In this article, we present a level-1 rhomboid glandular rotational flaps (GRF) that can effectively treat any quadrant defect that involves excision of less than 20% of the breast volume in select patients. This paper provides details on patient selection, surgical technique, and potential complications associated with this procedure.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 7","pages":"Pages 667-671"},"PeriodicalIF":2.5,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extended Discussion on the Dutch Study: Future Directions for Precision in Chemotherapy Indications for Breast Cancer.","authors":"Mufeng Liang","doi":"10.1016/j.clbc.2025.06.013","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.06.013","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding the Clinical Utility of the Modified Frailty Index in Mastectomy Patients: A Call for Prospective, Multidimensional Validation.","authors":"Qi Xu, Xiaohui Chen","doi":"10.1016/j.clbc.2025.06.012","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.06.012","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics, Treatment Patterns and Clinical Outcomes of Women with Maghreb Origin and Diagnosis of Breast Cancer: A Single-Center, Retrospective Cohort Study.","authors":"Chiara Dauccia, Diogo Martins-Branco, Michel Moreau, Lieveke Ameye, Elisa Agostinetto, Luca Arecco, Soraia Lobo-Martins, Anja Skoporc, Isabel Vilas-Boas, Masa Auprih, Ahmad Awada, Véronique Debien, Evandro de Azambuja","doi":"10.1016/j.clbc.2025.06.011","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.06.011","url":null,"abstract":"<p><strong>Background: </strong>Disparities in breast cancer (BC) prevention, screening, treatment access, and survival based on ethnicity have been described. Data in Arab population are limited. We aimed to dissect differences in BC characteristics and outcomes among patients of Maghreb versus non-Maghreb origin.</p><p><strong>Methods: </strong>We retrospectively analyzed women of Maghreb origin treated at Institut Jules Bordet for invasive BC between January 2000 and September 2018. Maghreb origin was identified by birthplace and/or first name. A sample of non-Maghreb patients was used for comparison. Multivariate models were adjusted for clinically relevant confounders.</p><p><strong>Results: </strong>We identified 282 Maghreb-origin patients and 277 non-Maghreb origin patients. At diagnosis, Maghreb-origin patients were younger (49.3 y, interquartile range [IQR] 40.8-58.1 vs. 62 y, IQR 52.3-72.2), had larger tumors, more clinical node-positive disease (37.6 vs. 22.5%) and more frequently presented symptoms (77.5% vs. 60.9%) (all P < .001). Maghreb-origin patients had a higher proportion of grade 3 (51.3% vs. 29.2%), HER2-positive (22.5% vs. 14.2%) and triple-negative (14.2% vs. 6.6%) tumors and more frequently received neoadjuvant chemotherapy (39.4% vs. 15.5%) and axillary lymph node dissections (73.9% vs. 56.1%) (all P < .001). After a median follow-up of 7.2 years, no statistically significant differences in iDFS (adjusted HR 1.11, 95% CI 0.72-1.73) or OS (adjusted HR 1.40, 95% CI 0.81-2.42) were observed.</p><p><strong>Conclusions: </strong>Despite the younger age and more aggressive BC, survival outcomes in patients of Maghreb vs. non-Maghreb origin did not differ. These results underscore the importance of considering ethnic minority populations to develop tailored prevention strategies and improve their inclusion in clinical trials.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thirty-Five-Year Follow-Up Real-World Data Revealed the Efficacy of Autologous Formalin-Fixed Tumor Vaccine on Metastatic Breast Cancer-A Target Trial Emulation.","authors":"Fumito Kuranishi, Tsubasa Miyazaki, Tomohiko Tagashira, Atsushi Fujii, Michimasa Yuba, Ichirou Miyake, Toyoaki Fujita, Toshiaki Suzuki, Hiroaki Masuda, Tetsuji Makihata, Shungo Nakagou, Tadao Ohno","doi":"10.1016/j.clbc.2025.06.008","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.06.008","url":null,"abstract":"<p><strong>Background and methods: </strong>The prognosis after distant metastasis of breast cancer is generally poor. We analyzed the effect of an autologous formalin-fixed tumor vaccine (AFTV) on postoperative breast cancer using 35-year follow-up real-world data in a concurrent cohort and a target trial emulation, a similar method to the randomized study. The sample (n = 698) was narrowed to cases with distant metastasis, resulting in a cohort of 94 patients. In this study, meta-OS refers to overall survival after distant metastasis.</p><p><strong>Results: </strong>Treatment with AFTV significantly prolonged meta-OS. The median meta-OS was 4.58 years for the AFTV group (n = 59) compared to 2.81 years for the control group (n = 35), with a significant difference (P = .0300). Radiotherapy (RT), a stratified factor, also extended meta-OS, although no superiority was observed between AFTV therapy and RT in multivariable regression analysis. The combination of AFTV therapy and RT demonstrated a synergistic effect in prolonging meta-OS (P = .0320). Chemotherapy (Chemo) alone showed no significant effect on meta-OS in the control group but shortened meta-OS in the AFTV group, if administered within 6 months of AFTV treatment (P = .0478). Treating after distant metastasis, the \"Optimum AFTV Set\" subgroup (AFTV therapy plus RT without Chemo within 6 months, n = 13) extracted from the AFTV group had a median meta-OS of 12.85 years, showing a significant improvement compared to the corresponding control subgroup (RT without Chemo within 6 months) (n = 6, P = .00819). The 10-year survival rate after distant metastasis was 25.6% in the AFTV group, 7.4% in the control group, 53.8% in the Optimum AFTV Set subgroup, and 0% in the corresponding control subgroup. All AFTV-related adverse events were classified as CTCAE grade 2 or lower.</p><p><strong>Discussion: </strong>The results of Optimum AFTV Set therapy provide a strong rationale for a larger-scale prospective randomized study.</p><p><strong>Conclusion: </strong>The present real-world data suggest that Optimum AFTV Set therapy may be a useful option for treatment following the detection of distant metastasis after breast cancer surgery.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overweight and Risk of Recurrence Following Neoadjuvant Chemotherapy in Breast Cancer","authors":"Anders Lerche Møller ,&nbsp;Signe Borgquist ,&nbsp;Ida Skarping","doi":"10.1016/j.clbc.2025.06.009","DOIUrl":"10.1016/j.clbc.2025.06.009","url":null,"abstract":"<div><h3>Background</h3><div>Having overweight is increasingly recognized as a risk factor for poor breast cancer (BC) outcomes. Previous studies have linked high body mass index (BMI) to an increased risk of recurrence and higher mortality. While most research has focused on patients treated with adjuvant chemotherapy, this study examines the impact of overweight on recurrence-free survival (RFS) in BC patients treated with neoadjuvant chemotherapy (NACT).</div></div><div><h3>Materials and methods</h3><div>This study included 490 Swedish BC patients who completed NACT between 2005 and 2019. During a follow-up period averaging 5 years, 116 patients (24%) experienced recurrences at any location. The association between overweight (BMI ≥ 25 kg/m²) at BC diagnosis and RFS was analysed using univariable and multivariable Cox regression models.</div></div><div><h3>Results</h3><div>The majority of patients (56%, 275/490) were classified as overweight. Patients with overweight tended to present with slightly more advanced disease stages and were more likely to have ER-/HER2- BC. Multivariable Cox regression analysis, adjusted for age and menopausal status, revealed that patients with overweight had a 47% higher hazard of recurrence compared to patients without overweight (hazard ratio [HR] 1.47, 95% CI 1.01-2.15). Subgroup analysis showed the largest relative effect in the ER+/HER2+ subgroup. Notably, the association between overweight and recurrence appeared independent of whether pathological complete response was achieved.</div></div><div><h3>Conclusions</h3><div>Overweight was associated with a higher risk of recurrence following NACT. Future research should explore whether BC prognosis can be improved by addressing modifiable factors that may mediate the impact of overweight on recurrence.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 7","pages":"Pages 658-666.e3"},"PeriodicalIF":2.5,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144803722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}